Registry update — unassessed
Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)
Trial registry update: WITHDRAWN. No results reported in the supplied registry record.
RCTN=60Notable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 29, 2022 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- No efficacy findings are reported, so we cannot assess whether fisetin affected pain, function, or any biomarkers.
- The trial design and rationale are described but outcomes are not, making it impossible to determine if the study was completed or what it found.
- Even with results, a 3-month trial in a chronic progressive disease would not establish long-term clinical benefit or whether senolytic effects translate to meaningful symptom or disease modification.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 60
- Duration
- 3 months
- Population
- Patients with mild to moderate knee osteoarthritis
- Primary outcome
- Pain and functional impairment in knee osteoarthritis
- Effect size
- —
- Significance
- Not reported
- Journal
- Austin V Stone
- Published
- Jul 29, 2022
Sources
Primary source
- Austin V Stone ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
double-blind, randomized clinical trial
compare 2 fisetin dosing regimens versus placebo
Sixty patients with mild to moderate knee OA will be assessed at baseline and 3 months
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.